To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

Total study duration up to 74 weeks: screening up to 4 weeks, AID assessment phase 12 weeks,
extension phase 52 weeks, post-treatment follow-up of 6 weeks.

For patients not entering the extension phase, total study duration up to 22 weeks
(screening, AID assessment phase and follow-up).

Inclusion criteria:

- Diagnosis of rheumatoid arthritis (RA), ≥3 months disease duration

- Patient willing and able to self-inject

- Continuous treatment with 1 or a combination of nonbiologic DMARDs (except
leflunomide in combination with methotrexate)

- Moderate-to-severely active RA

Exclusion criteria:

- Patients<18 years

- Prior treatment with anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonists

- Treatment with tumor necrosis factor (TNF) antagonists

- Treatment with RA-directed biologic agents other than with a TNF-α antagonist
mechanism as follows: Anakinra, Abatacept, Rituximab or other cell-depleting agent

- Prior treatment with a Janus kinase inhibitor

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.